Abstract: Objective To explore the dosimetry and toxicity of early-course simultaneous integrated boost volume rotation intensity-modulated radiotherapy for Ib2 cervical cancer. Methods A total of 31 patients with stage Ib2 cervical cancer who were treated with volume rotation intensity-modulated radiotherapy in Xuzhou Central Hospital from December 2017 to December 2018 were selected as the research subjects. The patients chose different radiotherapy methods independently, and were assigned to a study group (treated with early-course simultaneous integrated boost volume rotation intensity-modulated radiotherapy, n=13) or a control group (treated with volume rotation intensity-modulated radiotherapy, n=18). The therapeutic effect and short-term adverse reactions of the two groups were observed. Results The hemostasis time in the study group was shorter than that in the control group and the complete response (CR) rate was higher than that in the control group (P<0.05). During the early-course radiotherapy, the tumor volume in the study group reduced faster than that in the control group; 30 days after radiotherapy, there was no statistical difference in tumor volume between the two groups (P>0.05). Compared with the control group, the study group presented increases in the mean dose to the small intestine as well as the irradiated volume of the bladder, rectum, pelvis and femoral head, without statistical differences (P>0.05). There was no statistical difference in the incidence of acute toxic reactions between the two group (P>0.05). Conclusions The implementation of early-course simultaneous integrated boost volume rotation intensity-modulated radiotherapy after radical hysterectomy achieves remarkable hemostatic effect, and rapidly reduces the tumor volume. At the same time, the incidence of toxic reactions remains low.